Ko Mei-Chuan, Woods James H, Fantegrossi William E, Galuska Chad M, Wichmann Jürgen, Prinssen Eric P
Department of Pharmacology, University of Michigan, Ann Arbor, MI 48109-5632, USA.
Neuropsychopharmacology. 2009 Aug;34(9):2088-96. doi: 10.1038/npp.2009.33. Epub 2009 Mar 11.
Behavioral effects of a nonpeptidic NOP (nociceptin/orphanin FQ Peptide) receptor agonist, Ro 64-6198, have not been studied in primate species. The aim of the study was to verify the receptor mechanism underlying the behavioral effects of Ro 64-6198 and to systematically compare behavioral effects of Ro 64-6198 with those of a mu-opioid receptor agonist, alfentanil, in monkeys. Both Ro 64-6198 (0.001-0.06 mg/kg, s.c.) and alfentanil (0.001-0.06 mg/kg, s.c.) produced antinociception against an acute noxious stimulus (50 degrees C water) and capsaicin-induced allodynia. An NOP receptor antagonist, J-113397 (0.01-0.1 mg/kg, s.c.), dose-dependently produced rightward shifts of the dose-response curve of Ro 64-6198-induced antinociception. The apparent pA(2) value of J-113397 was 8.0. Antagonist studies using J-113397 and naltrexone revealed that Ro 64-6198 produced NOP receptor-mediated antinociception independent of mu-opioid receptors. In addition, alfentanil dose-dependently produced respiratory depression and itch/scratching responses, but antinociceptive doses of Ro 64-6198 did not produce such effects. More important, Ro 64-6198 did not produce reinforcing effects comparable with those of alfentanil, cocaine, or methohexital under self-administration procedures in monkeys. These results provide the first functional evidence that the activation of NOP receptors produces antinociception without reinforcing effects in primates. Non-peptidic NOP receptor agonists may have therapeutic value as novel analgesics without abuse liability in humans.
一种非肽类孤啡肽(痛敏肽/孤啡肽FQ肽)受体激动剂Ro 64-6198对灵长类动物行为的影响尚未得到研究。本研究的目的是验证Ro 64-6198行为效应背后的受体机制,并在猴子中系统比较Ro 64-6198与μ-阿片受体激动剂阿芬太尼的行为效应。Ro 64-6198(0.001-0.06 mg/kg,皮下注射)和阿芬太尼(0.001-0.06 mg/kg,皮下注射)均能产生针对急性伤害性刺激(50℃水)和辣椒素诱导的痛觉过敏的镇痛作用。一种孤啡肽受体拮抗剂J-113397(0.01-0.1 mg/kg,皮下注射)剂量依赖性地使Ro 64-6198诱导的镇痛剂量-反应曲线右移。J-113397的表观pA(2)值为8.0。使用J-113397和纳曲酮的拮抗剂研究表明,Ro 64-6198产生的孤啡肽受体介导的镇痛作用独立于μ-阿片受体。此外,阿芬太尼剂量依赖性地产生呼吸抑制和瘙痒/抓挠反应,但Ro 64-6198的镇痛剂量未产生此类效应。更重要的是,在猴子的自我给药程序中,Ro 64-6198未产生与阿芬太尼、可卡因或甲己炔巴比妥相当的强化作用。这些结果提供了首个功能证据,表明在灵长类动物中,孤啡肽受体的激活产生镇痛作用而无强化作用。非肽类孤啡肽受体激动剂作为新型镇痛药在人类中可能具有治疗价值且无滥用倾向。